In 1896, Beatson performed the first oophorectomy on two premenopausal patients with advanced breast cancer and saw good results with the cancer regressing after surgery. This caused great excitement in the medical community at the time. In 1905, the use of radiation to remove the function of the ovaries was invented to treat breast cancer. Which patients are suitable for ovarian debulking treatment? Current research shows that it depends on whether the breast cancer is hormone-dependent or non-hormone-dependent, only patients with estrogen-dependent breast cancer are suitable for ovarian debulking, while the latter category is not necessarily effective. Clinically, ovarian debulking can be considered as hormone-dependent if the breast cancer has axillary lymph node metastasis or if the pain and swelling of both breasts are more obvious when menstruation usually occurs. In other words, if the patient’s tumor is estrogen receptor positive, especially if there is extensive metastasis in the axillary lymph nodes or metastasis in the subclavian lymph nodes, it is suitable for debulking treatment. Patients who are pre-menopausal or less than 5 years post-menopausal, patients who have recurrence of breast cancer after mastectomy but are not suitable for radiotherapy, especially those who are estrogen receptor positive, can also be considered for ovarian debulking treatment. After oophorectomy, the tumor shrinks and the symptoms are relieved for a period of time, but the treatment effect will not last forever. Factors affecting the efficacy of ovarian denervation include: (1) Age: Patients who undergo ovarian denervation before or within 1 year after menopause have good efficacy; those who are menopausal for more than 1 year are often ineffective or rarely effective. Premenopausal patients are most effective at the age of 46 to 50 years, with an average of 37% to 40%; while only 22% of patients under the age of 35 years are effective. (2) Menstrual condition: The efficiency is higher for those with regular menstruation, about 34.5%; for those with irregular menstruation, 27%. (3) The interval between surgery and recurrence: The longer the interval between surgery and recurrence, the higher the effective rate. For those within 1 year, 28% were effective; 34% for those 2-4 years; 55% for those over 5 years. (4) Site of recurrence: 40% for those with localized breast, supraclavicular lymph nodes and soft tissue; 26% for those with metastases in bone, pleura and lung; 8.6% for those with metastases in liver and peritoneum; ineffective for those with brain metastases. (5) Estrogen receptor and progesterone receptor: The efficiency of estrogen receptor (ER) positive patients is 60% to 70%; negative patients are rarely effective. 80% efficiency can be achieved for both ER and progesterone receptor positive patients. Patients with ovarian decompensation are prone to cardiovascular disease, and their serum cholesterol and triglycerides are higher than those of decompensated patients. In patients who have been menopausal for many years, the ovaries may have atrophied and lost their function, and denervation is no longer meaningful. For patients with smaller local recurrences and distant metastases, local radiotherapy is still the first choice, and then neoplastic treatment will be considered when there are further metastases. Therefore, it is important to choose the time of desmoid treatment.